Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-trace').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67eb0ff1dc9ea-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-code').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-context').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67eb0ff1dc9ea-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67eb0ff1dc9ea-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 2337,
		&#039;title&#039; =&gt; &#039;Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;
&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 30 June, 2010, http://www.hindu.com/2010/06/30/stories/2010063064491100.htm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 2421,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 2337,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings,...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;font &gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 2337,
	&#039;title&#039; =&gt; &#039;Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;
&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 30 June, 2010, http://www.hindu.com/2010/06/30/stories/2010063064491100.htm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 2421,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 2337
$metaTitle = &#039;LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings,...&#039;
$disp = &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;font &gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr | Im4change.org</title>
    <meta name="description" content="




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings,..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Three firms rank highest on access to poor by Donald G. Mcneil Jr</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p align="justify"><font ></font></p><p align="justify"><br /><font >GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.</font></p><p align="justify"><font >European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.</font></p><p align="justify"><font >The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.</font></p><p align="justify"><font >Gilead Sciences and Pfizer rose several ranks from 2008.</font></p><p align="justify"><font >Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).</font></p><p align="justify"><font >The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &ldquo;report cards&rdquo; on 20 companies.</font></p><p align="justify"><font >For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. &mdash; New York Times News Service</font></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-trace').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67eb0ff1dc9ea-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-code').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-context').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67eb0ff1dc9ea-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67eb0ff1dc9ea-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 2337,
		&#039;title&#039; =&gt; &#039;Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;
&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 30 June, 2010, http://www.hindu.com/2010/06/30/stories/2010063064491100.htm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 2421,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 2337,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings,...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;font &gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 2337,
	&#039;title&#039; =&gt; &#039;Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;
&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 30 June, 2010, http://www.hindu.com/2010/06/30/stories/2010063064491100.htm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 2421,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 2337
$metaTitle = &#039;LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings,...&#039;
$disp = &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;font &gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr | Im4change.org</title>
    <meta name="description" content="




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings,..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Three firms rank highest on access to poor by Donald G. Mcneil Jr</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p align="justify"><font ></font></p><p align="justify"><br /><font >GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.</font></p><p align="justify"><font >European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.</font></p><p align="justify"><font >The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.</font></p><p align="justify"><font >Gilead Sciences and Pfizer rose several ranks from 2008.</font></p><p align="justify"><font >Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).</font></p><p align="justify"><font >The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &ldquo;report cards&rdquo; on 20 companies.</font></p><p align="justify"><font >For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. &mdash; New York Times News Service</font></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-trace').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67eb0ff1dc9ea-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-code').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eb0ff1dc9ea-context').style.display = (document.getElementById('cakeErr67eb0ff1dc9ea-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67eb0ff1dc9ea-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67eb0ff1dc9ea-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 2337,
		&#039;title&#039; =&gt; &#039;Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;
&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 30 June, 2010, http://www.hindu.com/2010/06/30/stories/2010063064491100.htm&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 2421,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 2337,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings,...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;font &gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 2337,
	&#039;title&#039; =&gt; &#039;Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;font face=&quot;arial,helvetica,sans-serif&quot; size=&quot;3&quot;&gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;
&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 30 June, 2010, http://www.hindu.com/2010/06/30/stories/2010063064491100.htm&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 2421,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 2337
$metaTitle = &#039;LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr&#039;
$metaKeywords = &#039;Health&#039;
$metaDesc = &#039;




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings,...&#039;
$disp = &#039;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;font &gt;GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world&#039;s poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Gilead Sciences and Pfizer rose several ranks from 2008.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &amp;ldquo;report cards&amp;rdquo; on 20 companies.&lt;/font&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;font &gt;For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy&#039;s, took the top three spots. &amp;mdash; New York Times News Service&lt;/font&gt;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr | Im4change.org</title>
    <meta name="description" content="




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings,..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Three firms rank highest on access to poor by Donald G. Mcneil Jr</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p align="justify"><font ></font></p><p align="justify"><br /><font >GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.</font></p><p align="justify"><font >European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.</font></p><p align="justify"><font >The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.</font></p><p align="justify"><font >Gilead Sciences and Pfizer rose several ranks from 2008.</font></p><p align="justify"><font >Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).</font></p><p align="justify"><font >The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &ldquo;report cards&rdquo; on 20 companies.</font></p><p align="justify"><font >For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. &mdash; New York Times News Service</font></p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 2337,
		'title' => 'Three firms rank highest on access to poor by Donald G. Mcneil Jr',
		'subheading' => '',
		'description' => '<p align="justify">
<font face="arial,helvetica,sans-serif" size="3"></font>
</p>
<p align="justify">
<br />
<font face="arial,helvetica,sans-serif" size="3">GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Gilead Sciences and Pfizer rose several ranks from 2008.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &ldquo;report cards&rdquo; on 20 companies.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. &mdash; New York Times News Service</font>
</p>
',
		'credit_writer' => 'The Hindu, 30 June, 2010, http://www.hindu.com/2010/06/30/stories/2010063064491100.htm',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 2421,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 2337,
	'metaTitle' => 'LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr',
	'metaKeywords' => 'Health',
	'metaDesc' => '




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings,...',
	'disp' => '<p align="justify"><font ></font></p><p align="justify"><br /><font >GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.</font></p><p align="justify"><font >European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.</font></p><p align="justify"><font >The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.</font></p><p align="justify"><font >Gilead Sciences and Pfizer rose several ranks from 2008.</font></p><p align="justify"><font >Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).</font></p><p align="justify"><font >The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &ldquo;report cards&rdquo; on 20 companies.</font></p><p align="justify"><font >For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. &mdash; New York Times News Service</font></p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 2337,
	'title' => 'Three firms rank highest on access to poor by Donald G. Mcneil Jr',
	'subheading' => '',
	'description' => '<p align="justify">
<font face="arial,helvetica,sans-serif" size="3"></font>
</p>
<p align="justify">
<br />
<font face="arial,helvetica,sans-serif" size="3">GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Gilead Sciences and Pfizer rose several ranks from 2008.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &ldquo;report cards&rdquo; on 20 companies.</font>
</p>
<p align="justify">
<font face="arial,helvetica,sans-serif" size="3">For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. &mdash; New York Times News Service</font>
</p>
',
	'credit_writer' => 'The Hindu, 30 June, 2010, http://www.hindu.com/2010/06/30/stories/2010063064491100.htm',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'three-firms-rank-highest-on-access-to-poor-by-donald-g-mcneil-jr-2421',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 2421,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 2337
$metaTitle = 'LATEST NEWS UPDATES | Three firms rank highest on access to poor by Donald G. Mcneil Jr'
$metaKeywords = 'Health'
$metaDesc = '




GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings,...'
$disp = '<p align="justify"><font ></font></p><p align="justify"><br /><font >GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did.</font></p><p align="justify"><font >European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom.</font></p><p align="justify"><font >The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases.</font></p><p align="justify"><font >Gilead Sciences and Pfizer rose several ranks from 2008.</font></p><p align="justify"><font >Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey).</font></p><p align="justify"><font >The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed &ldquo;report cards&rdquo; on 20 companies.</font></p><p align="justify"><font >For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. &mdash; New York Times News Service</font></p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Three firms rank highest on access to poor by Donald G. Mcneil Jr

GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information; two years ago, only about half did. European companies slightly edged U.S. companies in the rankings, while the four Japanese companies ranked were at or near the bottom. The companies are graded on many factors, including whether they offer lower prices or donate drugs in poor countries, whether they license generic versions of their products or fight to prevent them, whether they donate expertise or money to struggling health systems and whether they do research on neglected diseases. Gilead Sciences and Pfizer rose several ranks from 2008. Those falling in rank were Novo Nordisk, Bayer, Bristol-Meyers Squibb and Merck KGaA (a German company no longer connected to the Merck based in New Jersey). The index, which is supported by the Bill and Melinda Gates Foundation, the Dutch and British governments, Oxfam and other donors, also issued detailed “report cards” on 20 companies. For the first time, generic drugmakers were ranked separately. Three Indian companies, Ranbaxy Laboratories, Cipla and Dr. Reddy's, took the top three spots. — New York Times News Service